ClinicalTrials.gg
CompletedNCT00094016Updated Nov 23, 2021

Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children

A Phase 3 interventional study of beclomethasone dipropionate in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 39 sites in 2 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-11-23.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
8th of 40
440 · median 67
Started
2004
with 5 others
Phase 3
20 of 40
none open now
Registered
2nd of 40
by date
Lead sponsor
7 of 40
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 40 studies testing beclomethasone in Asthma, this one is the 8th largest by enrollment, is one of 6 that started in 2004, is one of 20 in phase 3, and was the 2nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

The primary objective of this study is to compare the QVAR-Easi-Breathe 100 mcg/day and QVAR-Easi-Breathe 200 mcg/day with placebo relative to changes in forced expiratory volume in 1 second (FEV1) results following 12 weeks of treatment. Secondary objectives such as daily asthma symptoms scores (per week), morning peak expiratory flow (PEF) values, nocturnal awakening and utilization of rescue medication per day also will be evaluated. In addition, an exploratory evaluation will assess the comparability of the two devices (i.e., QVAR-Easi-Breathe versus QVAR-MDI) at the same dose levels.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female children aged 5 through 11 years at the screening visit
  • Documented clinical evidence of asthma ( = 65-90%)
  • Ability to perform acceptable and reproducible spirometry per ATS guidelines
  • Ability to perform PEF determinations
  • Reversible bronchoconstriction as verified by >12% increase in FEV1
  • Otherwise healthy children with clinically-acceptable medical history, physical examination, vital signs and clinical laboratory parameters within the acceptable ranges for asthma patients
  • The parent or guardian must be willing to give written as well as the patient assent and be able to adhere to the dose and visit schedule.

Exclusion criteria

Exclusion Criteria:

  • Patients who have used inhaled within 30 days prior to the screening visit.
  • Allergy or sensitivity to beclomethasone dipropionate (BDP) or to other components of the formulations used in the CTM
  • Patients demonstrating an increase or decrease in >20% between the screening and baseline visit.
  • Patients who are unable to use a metered dose inhaler (MDI) without a spacer device.
  • Patients requiring the use of >12 puffs per day of albuterol for any 3 consecutive days between the screening and baseline visits.
  • Patients with evidence of growth retardation
  • Patients who have been treated with methotrexate, cyclosporin, gold or other cytotoxic agents for the control of asthma or for a concurrent condition within the last 3 months.
  • Patients who are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy for rhinitis.
  • Patients with evidence (on physical exam) of oropharyngeal candidiasis.
  • Exposure to drugs within 30 days prior to the screening visit
  • Require continuous treatment with beta blockers MAO inhibitors, tricyclic antidepressants, anticholinergics, inhaled nedocromil or cromolyn, or nebulized therapy (excluding sponsor provided albuterol MDI)
  • Inability to tolerate or unwillingness to comply with required for all applicable medications
  • Treatment at any time for life-threatening asthmatic episodes (e.g., episodes requiring intubation and/or associated with the development of hypercapnia, hypoxia and seizures, etc.)
  • Patients that have received any of the following treatments or met any of the following conditions within six weeks prior to the screening visit:

    • Oral or injectable corticosteroids
    • an upper respiratory tract infection and/or sinusitis associated with exacerbation of asthmatic symptoms
    • emergency room treatment or hospitalization for asthmatic symptoms.
  • History and/or presence of any non-asthmatic acute or chronic lung disease, including but not limited to bronchitis (within the previous 6 months), emphysema, active tuberculosis, bronchiectasis or cystic fibrosis.
  • Presence of any clinically-significant cardiovascular disease (including cardiac arrhythmias and uncontrolled hypertension), clinically-significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled diabetes, hyperthyroidism, convulsive disorders, neoplastic disease other than basal cell carcinoma, and significant psychiatric disease.
  • History of glaucoma or cataracts
  • Presence of systemic fungal, bacterial, viral or parasitic infections and/or ocular herpes simplex
  • Unlikely to be compliant, take study medication as directed, complete the diary cards, or attend scheduled clinic visits as required.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
440 participants
06

Study locations

39 sites
  • Allergy and Asthma Specialists
    Huntington Beach, California 92647, United States
  • Pediatric Care Medical Group
    Huntington Beach, California 92647, United States
  • West Coast Clinical Trials
    Long Beach, California 90806, United States
  • Southern California Research
    Mission Viejo, California 92691, United States
  • Clinical Trials of Orange County, Inc.
    Orange, California 92868, United States
  • California Allergy & Asthma
    Palmdale, California 93551, United States
  • Center for Clinical Trials, LLC
    Paramount, California 90723, United States
  • Integrated Research Group
    Riverside, California 92506, United States
  • Allergy Associates Medical Group
    San Diego, California 92120, United States
  • Allergy and Asthma Medical Group
    Walnut Creek, California 94598, United States
  • Allergy & Asthma Care of Florida
    Ocala, Florida 34471, United States
  • New Horizon's Health Research
    Atlanta, Georgia 30309, United States
  • AeroAllergy Research Labs of Savanna, Inc
    Savannah, Georgia 31406, United States
  • Sneeze, Wheeze and Itch Associates
    Normal, Illinois 61761, United States
  • Family Allergy & Asthma Research Institute
    Louisville, Kentucky 40215, United States
  • Perez-Betancourt Medical Clinic
    Metairie, Louisiana 70001, United States
  • NorthEast Medical Research Associates
    North Dartmouth, Massachusetts 02747, United States
  • Clinical Research Institute
    Plymouth, Minnesota 55441, United States
  • The Asthma and Allergy Center
    Papillion, Nebraska 68046-4194, United States
  • Asthma and Allergy Associates, PC
    Ithaca, New York 14850, United States
  • St.Elizabeth's Children's Health Center
    Utica, New York 13502, United States
  • Regional Allergy and Asthma Consultants
    Asheville, North Carolina 28805, United States
  • Allergy & Respiratory Center
    Canton, Ohio 44718, United States
  • Dayton Clinical Research Center
    Dayton, Ohio 45406, United States
  • Dr. Santiago Reyes
    Oklahoma City, Oklahoma 73112, United States
  • Allergy and Asthma Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Allergy and Asthma Research Groups
    Eugene, Oregon 97401, United States
  • Allergy, Asthma & Dermatology Research Center
    Lake Oswego, Oregon 97035, United States
  • Clinical Research Institute of Southern Oregon, PC
    Medford, Oregon 97504, United States
  • Allergy Associates Research Center
    Portland, Oregon 97213, United States
  • Allergy & Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • The Allergy Asthma and Sinus Center
    Knoxville, Tennessee 37922, United States
  • Pediatric Allergy/Immunology Assoc.
    Dallas, Texas 75230, United States
  • Pharmaceutical Research and Consulting, Inc.
    Dallas, Texas 75231, United States
  • Allergy and Asthma Associates
    Houston, Texas 77054, United States
  • Virginia Adult & Pediatric Allergy & Asthma
    Richmond, Virginia 23229, United States
  • Spokane Allergy and Asthma Clinical Research
    Spokane, Washington 99204, United States
  • Centro Neumologia Pediatrica
    Hato Rey, 00917, Puerto Rico
  • Ponce School of Medicine
    Ponce, 00732, Puerto Rico
07

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2004 to primary completion in Jun 2006, 19 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 19 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2004
First posted
Oct 11, 2004
StartActual
Oct 31, 2004
Primary completionActual
Jun 30, 2006
CompletionActual
Jun 30, 2006
Last update
Nov 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00094016
Responsible party
Sponsor
First posted
Oct 11, 2004
Start date
Oct 31, 2004
Primary completion
Jun 30, 2006
Completion
Jun 30, 2006
Last update
Nov 23, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion